



- Confusion
- Chills/shaking chills
- Fever (100.4°F/38°C or higher)
- Difficulty breathing
- Severe nausea, vomiting, diarrhea
- Severe muscle or joint pain
- Very low blood pressure
- Dizziness/light-headedness
- Headache

**SIGNS AND SYMPTOMS MAY INCLUDE:**

**Call your oncologist or go to the emergency room if these signs appear.**  
Kymriah may cause side effects that are severe or life-threatening.

**Patient Information**

## PATIENT WALLET CARD

**Have This Card With You At All Times  
Show It To Any Doctor That Sees You And When  
You Go To The Hospital**

You should plan to stay within 2 hours of the location where you received your treatment for at least 4 weeks after getting Kymriah. Your healthcare provider will check to see if your treatment is working and help you with any side effects that occur.

## INFORMATION FOR THE HEALTHCARE PROVIDER

This patient has received Kymriah (CAR-T cell) therapy

**Following Kymriah treatment, Cytokine Release Syndrome (CRS) can happen. It may include neurological toxicities.**



**Please contact his/her treating oncologist in the following situations:**

- before giving steroids or cytotoxic medications
- if the patient has a serious infection
- before the patient undergoes an invasive procedure

fold

fold

Date received Kymriah: \_\_\_\_\_

Oncologist Name (for Kymriah therapy): \_\_\_\_\_

Phone Number: \_\_\_\_\_

Kymriah is a CD19-directed genetically modified autologous T Cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse and adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Limitation of Use: KYMRIAHA is not indicated for treatment of patients with primary central nervous system lymphoma

 **KYMRIAHA**<sup>®</sup>  
(tisagenlecleucel) Suspension  
for IV infusion